Answers are grounded in this paper and cite their sources.
The diagnosis of metabolic dysfunction-associated steatotic liver disease (MASLD) requires at least one of five cardiometabolic criteria. It is unclear whether these criteria can be used as predictors and treatment targets for complications including liver-related events and major adverse cardiovascular events (MACE).
No takes yet. Share an insight, caveat, or question.
Tamaki et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: